Silverback Therapeutics (NASDAQ:SBTX) Stock Price Down 0.6% – Here’s Why

Silverback Therapeutics, Inc. (NASDAQ:SBTX)’s share price was down 0.6% during trading on Monday . The company traded as low as $9.05 and last traded at $9.28. Approximately 660,760 shares traded hands during mid-day trading, an increase of 96% from the average daily volume of 337,931 shares. The stock had previously closed at $9.34.

Silverback Therapeutics Stock Down 1.2%

The firm has a market cap of $330.65 million, a PE ratio of -3.79 and a beta of 0.60. The stock has a 50 day moving average price of $10.35 and a two-hundred day moving average price of $10.24.

Silverback Therapeutics Company Profile

Silverback Therapeutics, Inc (NASDAQ: SBTX) is a clinical-stage biotechnology company focused on developing next-generation immunotherapies for cancer. The company’s proprietary ImmunoTAC™ (tumor-activated cytokine) platform is designed to harness the innate immune system by conjugating toll-like receptor agonists to tumor-targeting antibodies. This modular approach aims to deliver immune-activating molecules directly to the tumor microenvironment, potentially improving the safety and efficacy profiles of existing immunomodulatory therapies.

Silverback’s pipeline includes multiple antibody-TLR agonist conjugates in early-phase clinical trials, each directed against distinct tumor-associated antigens.